Applying Machine Learning to Genomic and Clinical Data

Genomic and clinical datasets look nothing like the tidy, balanced datasets used in most ML tutorials. Here are the challenges that come up constantly in practice, and the standard ways to deal with them.

1. High dimensionality, few samples

A gene expression dataset might have 20,000 features (one per gene) but only a few hundred patients. This is the opposite of what most ML methods expect, and it makes overfitting the default failure mode rather than an edge case.

What helps: feature selection driven by biological knowledge (rather than throwing every feature at the model), regularisation (L1/L2 penalties), and dimensionality reduction before modelling.

2. Severe class imbalance

Rare diseases are, definitionally, rare. A dataset for a rare genetic disorder might have 50 cases and 50,000 controls. A naive model can get 99.9% accuracy by predicting "negative" every time - and be completely useless.

What helps: resampling techniques (SMOTE, class weighting), and - critically - reporting sensitivity/specificity/AUC instead of raw accuracy so a lazy model can't hide.

3. Multi-modal data

Real clinical predictions often combine structured data (lab values, red blood cell indices) with unstructured data (microscope images, free-text clinical notes). This was the core design problem in my own published work - a model combining blood indices and smartphone-captured microscopic images for β-thalassemia screening performs better than either modality alone, because they carry complementary information.

What helps: dual-branch architectures that process each modality separately (a CNN for images, a simpler model for tabular values) and fuse the learned representations before the final prediction.

4. Interpretability isn't optional

A clinician (correctly) won't act on a prediction they can't understand. "The model said 87% probability of pathogenicity" is not a clinically actionable statement on its own.

What helps: simpler, inherently interpretable models where possible (logistic regression, decision trees); SHAP or LIME values to explain individual predictions from more complex models; and always reporting a confidence/uncertainty estimate alongside a prediction, not just a point estimate.

5. Validation has to be genuinely independent

A model can look excellent on held-out data from the same hospital, batch, or sequencing run, and fail on the next one - because it accidentally learned to recognise the batch, not the biology. Validating on a truly external cohort (different site, different time period) is the only way to know if a model will actually generalise.

Further reading

• Nature Reviews Genetics - Machine learning applications in genetics and genomics
• scikit-learn: Model evaluation
• PyTorch and TensorFlow - the two dominant deep learning frameworks